Psychosexual well-being in women using oral contraceptives containing drospirenone.
Considerable advances have been made in hormonal contraception in recent years, geared at maximizing compliance and minimizing discontinuation. In oral contraceptive (OC) formulations, the estrogenic component, generally ethinyl estradiol (EE), has been reduced significantly and newer progestins like dienogest and drospirenone (DRSP), compounds with different molecular structures, have been introduced; in addition, new regimens (extended, flexible, 24/4 formats instead of the standard 21/7 format) and innovative delivery systems (vaginal rings, transdermal patches, subcutaneous implants and intrauterine devices) are available. The multitude of choices allows hormonal contraception to be tailored to the individual woman in order to obtain non-contraceptive benefits, without significant side effects, and also a favorable risk/benefit profile for her general and reproductive health. Over the past few years, new OC formulations combining DRSP (3 mg), a unique progestin with both antimineralocorticoid and antiandrogenic activities, with estrogen (30 mcg or 20 mcg EE), in two regimens (24/4 and 21/7) of active pills in a 28-day cycle, have shown positive effects on water retention-related weight gain and physical, emotional and psychosexual well-being. It seems likely that the use of a low-dose, well-balanced OC and the shorter 4-day hormone-free interval may minimize the side effects that can impair quality of life and thus increase women's compliance with hormonal contraception therapy.
Nappi
Rossella E
RE
Research Center for Reproductive Medicine, Section of Obstetrics and Gynecology, Department of Morphological, Eidological and Clinical Sciences, University of Pavia, Italy. renappi@tin.it
Albani
Francesca
F
Tonani
Silvia
S
Santamaria
Valentina
V
Pisani
Carla
C
Terreno
Erica
E
Martini
Ellis
E
Polatti
Franco
F
D000736:Androstenes / Q000008:administration & dosage* / Q000009:adverse effects; D002626:Chemistry, Pharmaceutical; D003276:Contraceptives, Oral / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D011788:Quality of Life; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced; D016387:Women's Health
D000736:Androstenes; D003276:Contraceptives, Oral; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone